ArticleClinical kidney journal2022
A real-world study on SGLT2 inhibitors and diabetic kidney disease progression.
Article in Clinical kidney journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 31 citations in OpenAlex.
- Review
- Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes.Clinical pharmacology and therapeutics · 2026Article
- Empagliflozin versus dapagliflozin for kidney outcomes in stage 3 chronic kidney disease: a propensity score-matched multi-center cohort study.BMC nephrology · 2026Article
- Protocol for Developing and Validating a Multimarker-Clinical Prediction Model of SGLT2 Inhibitor-Induced Acute eGFR Dip in CKD Stages 3-4: A Three-Stage Urinary Proteomics Study.Life (Basel, Switzerland) · 2026Article
- Target trial emulation of sodium glucose cotransporter 2 inhibitors and clinical outcomes in diabetes and end stage kidney disease.Scientific reports · 2026Article
- The effect of empagliflozin on renal outcomes compared to sitagliptin with type 2 diabetes: target trial emulation using electronic medical records.International journal of clinical pharmacy · 2026Article
- Early In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors After ST-Elevation Myocardial Infarction: A Clinical Review of Hemodynamic and Renal Safety.Reviews in cardiovascular medicine · 2026Review
- SGLT2 inhibitor role in cardio-metabolic-renal diseases: a narrative review of recent evidence and their pharmacological, clinical and economic implications.Drugs in context · 2026Review
- Heterogeneity in Economic Value of SGLT2is for Type 2 Diabetes: Subgroup Modeling Cost-Effectiveness Analyses.PharmacoEconomics · 2025Article
- Health economic evaluation of a risk-stratified intervention in diabetic kidney disease.Diabetologia · 2025Article
- Suboptimal physician adherence to evidence-based guidelines for managing cardiorenal comorbidities in diabetes care: A retrospective single-center study in Taiwan.Journal of diabetes investigation · 2025Observational
- Impact of Empagliflozin on Cardiovascular Outcomes and Renal Function in Patients with Obesity and Type 2 Diabetes: A Retrospective Cohort Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Efficacy and Safety of Low-Dose Spironolactone in Management of Diabetic Kidney Disease in a Real-World Setting.Endocrinology, diabetes & metabolism · 2025Article
- Sodium-Glucose Cotransporter-2 Inhibitors and Prevention of Adverse Kidney Outcomes in Type 2 Diabetes: A Clinical Multiethnic Asian Cohort.Kidney medicine · 2025Article
- Efficacy of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on proteinuria and weight in a diabetes cohort.World journal of diabetes · 2025Article
- Real-world effectiveness and safety of sodium-glucose co-transporter 2 inhibitors in chronic kidney disease.Scientific reports · 2025Article
- Factors affecting disease progression in early-stage chronic kidney disease in a multi-ethnic, southeast Asian primary care population.Frontiers in medicine · 2025Article
- Focal Segmental Glomerulosclerosis With Superimposed Infection-Related Glomerulonephritis in a Diabetic Patient: A Case of Rapid Renal Decline.Clinical case reports · 2024Article
- The Role of Sodium-Glucose Cotransporter-2 Inhibitors in the Treatment Paradigm of CKD in Africa: An African Association of Nephrology Panel Position Paper.Kidney international reports · 2024Article
- Nurse Practitioner Care Compared with Primary Care or Nephrologist Care in Early CKD.Clinical journal of the American Society of Nephrology : CJASN · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Randomized controlled trials have demonstrated the benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2is) in people with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). However, real-world data on CKD progression and the development of end-stage kidney disease (ESKD) remains scarce. Our aim was to study renal outcomes of people with diabetic kidney disease (DKD) using SGLT2is in a highly prevalent DKD population. Methods: Between 2016 and 2019 we recruited T2DM patients in the renal and diabetic clinics in a regional hospital in Singapore. Patients prescribed SGLT2is were compared with those on standard anti-diabetic and renoprotective treatment. The outcome measures were CKD progression [ Results: We analysed a total of 4446 subjects; 1598 were on SGLT2is. There was a significant reduction in CKD progression {hazard ratio [HR] 0.60 [95% confidence interval (CI) 0.49-0.74]} with SGLT2is. The HR for eGFR ≥45 mL/min/1.73 m Conclusions: This real-world study demonstrates the benefits of SGLT2is on CKD progression and ESKD. The effect is more pronounced in moderate to advanced CKD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.